Authorities in Henan, China approved changes in Henan Taloph Pharmaceutical Stock's (SHA:600222) drug production license for its honeysuckle dew drops and isatis root syrup, according to a Tuesday filing with the Shanghai bourse.
The company obtained approval for in-house production of its dew drops and syrup, the filing said.
The honeysuckle dew is used for pediatric sores and summer heat, while the syrup is indicated for colds and sore throat.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。